Three-Year Survival Outcomes to First-Line Cemiplimab Monotherapy in NSCLC With PD-L1 TPS 50% to 89% Versus Greater Than or Equal to 90% in EMPOWER-Lung 1. This evidence concerns the gene CD274 and non-small cell lung carcinoma.